MedTrace Logo

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

NCT01893515 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2015-10-30

No results posted yet for this study

Summary

The objectives of this study is

* To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameters from baseline after 12 weeks of treatment.
* To evaluate the safety of PRC-4016 as assessed by adverse events and other safety parameters

Conditions

Interventions

DRUG

PRC-4016

DRUG

Placebo

Sponsors & Collaborators

  • Pronova BioPharma

    lead INDUSTRY

Principal Investigators

  • Pål Nord, MD, MPH · Pronova BioPharma

  • Traci A. Turner, MD, MT · Metabolic and Atherosclerosis Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01893515 on ClinicalTrials.gov